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Abstract
Background: To investigate the association between pineal gland volume and symptoms of rapid eye movement
(REM) sleep behavior disorder (RBD) in Alzheimer’s disease (AD) patients without any feature of dementia with Lewy
bodies.
Methods: We enrolled 296 community-dwelling probable AD patients who did not meet the diagnostic criteria for
possible or probable dementia with Lewy bodies. Among them, 93 were amyloid beta (Aβ) positive on 18F-
florbetaben amyloid brain positron emission tomography. We measured RBD symptoms using the REM Sleep
Behavior Disorder Screening Questionnaire (RBDSQ) and defined probable RBD (pRBD) as the RBDSQ of 5 or higher.
We manually segmented pineal gland on 3T structural T1-weighted brain magnetic resonance imaging.
Results: The participants with pRBD had smaller pineal parenchyma volume (VPP) than those without pRBD
(p < 0.001). The smaller the VPP, the more severe the RBD symptoms (p < 0.001). VPP was inversely associated with
risk of prevalent pRBD (odds ratio = 0.909, 95% confidence interval [CI] = 0.878–0.942, p < 0.001). Area under the
receiver operator characteristic curve for pRBD of VPP was 0.80 (95% CI = 0.750–0.844, p < 0.0001). These results
were not changed when we analyzed the 93 participants with Aβ-positive AD separately.
Conclusions: In AD patients, reduced pineal gland volume may be associated with RBD.
Keywords: Alzheimer’s disease, Pineal gland, Rapid eye movement sleep behavior disorder, Magnetic resonance
imaging, Amyloid positron emission tomography
Background
Rapid eye movement (REM) sleep behavior disorder
(RBD) is a parasomnia characterized by loss of normal
skeletal muscle atonia accompanied by dream-enacting
behaviors [1]. A large autopsy study found that 94% of
the neurodegenerative disorders associated with RBD
were synucleinopathies and claimed that the presence of
RBD should at least raise suspicion of primary or coex-
isting Lewy body disease even in the typical Alzheimer’s
disease (AD) [2]. However, their claim seems somewhat
overextended. First of all, their study sample may not
represent overall RBD and be subject to a sampling bias
[2]. Second, RBD is also prevalent in cognitively normal
older adults [3], suggesting that RBD may occur without
synucleinopathy. AD is far more prevalent than synuclei-
nopathies [4], and RBD was quite common in numerous
cross-sectional and prospective studies on AD patients
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[5–15]. There is no reason to assume that AD patients
will develop RBD only from synucleinopathy, not the
pathologies that can lead to RBD in normal older adults
without synucleinopathy.
In cognitively normal older adults, the smaller pineal
gland was associated with more RBD symptoms and
higher risk of incident RBD symptoms, suggesting that
reduction of melatonin secretion associated with the re-
duction of pineal gland volume may be a potential cause
of RBD [16]. AD patients show reduced endogenous
melatonin levels [17] and have a smaller pineal gland
compared to healthy controls [18]. Pineal gland is a
small neuroendocrine organ, and its primary function is
to regulate sleep through the synthesis and secretion of
melatonin [19]. In humans, roughly 80% of the pineal
gland comprises melatonin-producing pinealocytes [19],
and pineal gland volume is proportional to the endogen-
ous melatonin levels [20, 21]. Pineal gland volume can
be changed by various physiological or pathological con-
ditions that may change melatonin production [16, 22].
In a couple of clinical trials, RBD symptoms such as
dream-enacting behaviors and REM sleep muscle atonia
were improved by the administration of melatonin [23,
24] but relapsed by its discontinuation [23]. However,
the association between pineal gland and RBD has never
been investigated in AD patients.
In this study, we investigated the association between
pineal gland volume and RBD symptoms in probable AD
patients who did not meet the diagnostic criteria of pos-
sible and probable dementia with Lewy bodies (DLB) [25].
Methods
Participants
We enrolled 296 community-dwelling probable AD from
the visitors to the Dementia Clinic of the Seoul National
University Bundang Hospital (SNUBH) from 2011 to
2020. Among them, 104 underwent a 18F-florbetaben
amyloid brain positron emission tomography (PET) scan,
and 93 were found to be amyloid beta (Aβ)-positive.
We excluded the participants with following condi-
tions: possible or probable DLB or Parkinson’s disease
dementia (PDD); any major psychiatric and/or neuro-
logical disorders that could affect cognitive function
other than AD; any history of brain tumors, substance
abuse or dependence, and use of medications such as
clonazepam or exogenous melatonin that may influence
RBD symptom; any serious medical conditions that
could affect the structure and/or function of the pineal
gland or abnormalities in pineal gland morphology such
as neoplastic lesions or extremely large cystic gland
(diameter greater than 15.0 mm) [26]; and those with
high risk of restless legs syndrome (positive on
Cambridge-Hopkins Restless Legs Syndrome question-
naire) [27] and obstructive sleep apnea (STOP-BANG
questionnaire score of ≥ 5 points) [28], all of which
could mimic symptoms of RBD [29, 30].
All participants were fully informed with the protocol
of this study, and provided written informed consents
signed by themselves or their legal guardians. This study
was approved by the Institutional Review Board of the
SNUBH.
Diagnostic assessments
Geriatric psychiatrists with expertise in dementia re-
search conducted in person standardized diagnostic in-
terviews, detailed medical histories, and physical/
neurological examinations using the Korean version of
the Consortium to Establish a Registry for Alzheimer’s
Disease Assessment Packet Clinical Assessment Battery
(CERAD-K) [31] and the Korean version of the Mini-
International Neuropsychiatric Interview [32]. Addition-
ally, research neuropsychologists administered the CERA
D-K Neuropsychological Assessment Battery (CERAD-
K-N) [31, 33], Digit Span Test [34], Frontal Assessment
Battery [35], and Geriatric Depression Scale [36].
Trained research nurses collected data on age, sex,
years of education, duration of AD (months), intracranial
volume (ICV), history of head injury, amount of smoking
(packs/day) and alcohol drinking (standard units/week)
over the past 12-month period, and use of drugs influen-
cing sleep or motor activity, including cholinesterase in-
hibitors (donepezil, rivastigmine, and galantamine),
antidepressants (selective serotonin reuptake inhibitor,
serotonin norepinephrine reuptake inhibitor, and
others), carbamazepine, triazolam, zopiclone, quetiapine,
clozapine, and sodium oxybate to each participant. We
diagnosed dementia according to the fourth edition of
the Diagnostic and Statistical Manual of Mental Disor-
ders Text Revision criteria [37]. Global severity of de-
mentia was determined according to the Clinical
Dementia Rating [38]. We determined probable AD ac-
cording to the National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s Dis-
ease and Related Disorders Association diagnostic cri-
teria [39]. We diagnosed probable or possible DLB and
PDD according to the diagnostic criteria proposed by
McKeith et al. [25], in which the presence of RBD fea-
tures was ignored in the current study.
Assessment of brain amyloid deposition
We performed 18F-florbetaben amyloid brain PET im-
aging using a Discovery VCT scanner (General Electric
Medical Systems; Milwaukee, WI, USA) in three-
dimensional (3D) acquisition mode. The participants
were injected with 8.1 mCi (300MBq) of 18F-florbetaben
(Neuraceq) as a slow single intravenous bolus (6 s/mL)
in a total volume of up to 10mL. After a 90-min uptake
period, we obtained 20-min PET images comprising four
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5-min dynamic frames. The determination was based on
the visual interpretation of tracer uptake in the gray
matter of the following four brain regions: the tem-
poral lobes, frontal lobes, posterior cingulate cortex/
precuneus, and parietal lobes. Participants were con-
sidered Aβ positive if smaller areas of tracer uptake
were equal to or higher than those present in the
white matter extending beyond the white matter rim
to the outer cortical margin involving the majority of
the slices within at least one of the four brain regions
(“moderate” Aβ deposition) or a large confluent area
of tracer uptake (i.e., signal intensity) was equal to or
higher than that present in the white matter extend-
ing beyond the white matter rim to the outer cortical
margin and involving the entire region including the
majority of slices within at least one of the four brain
regions (“pronounced” Aβ deposition). Participants
were considered Aβ negative if tracer uptake in the
gray matter is lower than that in the white matter in
all four brain regions (no β-amyloid deposition).
Assessment of rapid eye movement sleep behavior
disorder symptoms
We evaluated behavioral features of RBD using the REM
Sleep Behavior Disorder Screening Questionnaire
(RBDSQ) [40]. The RBDSQ is a self-reported screening
instrument used to diagnose RBD and comprises 10
items assessing the most prominent clinical features of
RBD: items 1 to 4, the frequency and content of dreams
and their relationship to nocturnal movements and be-
haviors; item 5, self-injuries and injuries to the bed part-
ner; item 6, four subsections specifically assessing
nocturnal motor behavior (e.g., questions about noctur-
nal vocalization (6.1), sudden limb movements (6.2),
complex movements (6.3), or bedside items that fall
down (6.4)); items 7 and 8, nocturnal awakenings; item
9, disturbed sleep in general; and item 10, the presence
of any neurological disorder. Each item could be an-
swered as “yes” or “no.” The RBDSQ score ranges from
0 to 13 points, with higher scores indicating more fea-
tures associated with RBD. We defined probable RBD
(pRBD) as having a total score of 5 or higher on the
RBDSQ [40]. The questionnaire was completed by the
participants with the corroboration from their partners.
Assessment of pineal gland volume
We obtained 3D structural T1-weighted spoiled gradient
echo magnetic resonance (MR) images using a Philips
3.0 Tesla Achieva scanner (Philips Medical Systems;
Eindhoven, the Netherlands) within 3months of clinical
assessments with the following parameters: acquisition
voxel size = 1.0 × 0.5 × 0.5 mm; sagittal slice thickness =
1.0 mm; repetition time = 4.61 ms; echo time = 8.15 ms;
number of excitations = 1; flip angle = 8°; field of view =
240 × 240mm; and acquisition matrix size = 175 × 256 ×
256mm in the x-, y-, and z-dimensions. We implemented
bias field correction to remove the signal intensity in-
homogeneity artifacts of MR images using Statistical Para-
metric Mapping software (version 12, SPM12; Wellcome
Trust Centre for Neuroimaging, London; http://www.fil.
ion.ucl.ac.uk/spm). We resliced the MR images into an
isotropic voxel size of 1.0 × 1.0 × 1.0 mm3. We measured
ICV using FreeSurfer software (version 5.3.0; http://surfer.
nmr.mgh.harvard.edu) to adjust for interindividual vari-
abilities in brain volume. We assessed pineal gland volume
as described in our previous work [16]. In brief, trained re-
searchers constructed a 3D mask of each pineal gland by
manually segmenting the pineal gland slice-by-slice on the
resliced T1-weighted MR images at 1.0 × 1.0 × 1.0mm3
using the ITK-SNAP software (version 3.4.0; http://www.
itksnap.org). We measured pineal gland volume and pin-
eal cysts volume and estimated the volume of pineal par-
enchyma (VPP) by subtracting the pineal cysts volume
from the pineal gland volume (Fig. 1). We defined a pineal
cyst as an area of homogenous intensity that was isoin-
tense to the cerebrospinal fluid in T1 sequence images
with a diameter of 2.0 mm or greater [41].
The intra-rater and inter-rater intraclass correlation
coefficient were 0.983 (95% confidence interval [CI] =
0.956–0.993, p < 0.001) and 0.934 (CI = 0.828–0.974,
p < 0.001), respectively.
Statistical analyses
We compared the continuous variables using the inde-
pendent samples t tests and categorical variables using
the chi-squared tests between groups. We compared
VPP between the participants with pRBD and those
without pRBD using analysis of covariance that adjusted
for age, sex, years of education, ICV, head injury, smok-
ing, alcohol drinking, and use of drugs influencing sleep
or motor activity as covariates. We examined the associ-
ation between VPP and the risk of pRBD using binary
logistic regression analysis that was adjusted for the
same covariates. We examined the diagnostic perform-
ance of the VPP for pRBD using the receiver operating
characteristic (ROC) analysis. We calculated the optimal
cutoff value and area under the curve (AUC) using You-
den index maximum (sensitivity + specificity − 1). We ex-
amined the association of VPP with RBDSQ total score
(RBDSQ-T) and the item-6 score of the RBDSQ
(RBDSQ-6) using multiple linear regression model ad-
justed for the covariates stated above. The RBDSQ item
6 comprises four subitems on the core symptoms of
RBD: nocturnal vocalization (6.1), sudden limb move-
ments (6.2), complex movements (6.3), or bedside items
that fall down (6.4). We conducted the same analyses
only on the Aβ-positive AD patients.
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For all analyses, we considered a two-tailed p value
less than 0.05 as statistically significant and employed
Bonferroni corrections to reduce type I error when mul-
tiple comparisons were conducted. We performed ROC
analyses using MedCalc for Windows version 18.11.3
(MedCalc Software, Mariakerke, Belgium) and all the
other statistical analyses using the Statistical Package for
the Social Sciences for Windows version 20.0 (Inter-
national Business Machines Corporation, Armonk, NY).
Results
As summarized in Table 1, the AD patients with pRBD
showed smaller VPP than those without pRBD (p <
0.001). VPP was inversely associated with the risk of
pRBD (odds ratio [OR] = 0.909, 95% CI = 0.878–0.942,
p < 0.001), indicating that the AD patients with smaller
VPP may be more likely to have pRBD than those with
smaller VPP. The AUC of VPP for pRBD was 0.80 (95%
CI = 0.750–0.844, p < 0.0001, Fig. 2a), and the optimal
cutoff value for classifying pRBD was 62 mm3 (sensitiv-
ity = 87.18%; specificity = 58.75%). VPP was also inversely
associated with the RBDSQ-T (standardized β = − 0.410,
p < 0.001) and the RBDSQ-6 (standardized β = − 0.224,
p < 0.001, Fig. 3a).
These results were not changed when we analyzed the
Aβ-positive AD patients separately. Among the 93 par-
ticipants with Aβ-positive AD, 11 (11.83%) had pRBD.
The Aβ-positive AD patients with pRBD showed smaller
Fig. 1 Assessment of pineal gland volume on 3D T1-weighted brain magnetic resonance images at 1.0 × 1.0 × 1.0 mm3. The pineal gland was
manually segmented from surrounding cerebrospinal fluid space
Table 1 Demographic and clinical characteristics of the participants
Without pRBD (n = 257) With pRBD (n = 39) p
Age (years, mean ± SD) 77.4 ± 7.4 76.8 ± 7.4 0.634a
Sex (women, %) 69.3 79.5 0.191a
Education (years, mean ± SD) 9.9 ± 5.6 8.1 ± 5.5 0.065a
Presence of cohabitants, (present, %) 80.5 74.4 0.371a
Duration of AD (months, mean ± SD) 36.9 ± 25.7 44.0 ± 37.8 0.265a
Drugs influencing sleep or motor activity (users, %) 29.2 38.5 0.240a
History of head injury (present, %) 9.0 10.3 0.792a
Alcohol drinking (SU/week, mean ± SD) 1.8 ± 7.1 0.7 ± 3.4 0.375a
Smoking (packs/day, mean ± SD) 0.1 ± 0.6 0.0 ± 0.2 0.750a
GDS (points, mean ± SD) 12.2 ± 6.9 16.5 ± 6.7 < 0.001a
CDR (points, mean ± SD) 0.7 ± 0.4 0.9 ± 0.5 0.903a
STOP-BANG (points, mean ± SD) 2.3 ± 0.9 2.6 ± 1.0 0.041a
RBDSQ (points, mean ± SD)
Total score 1.4 ± 1.2 6.1 ± 1.4 < 0.001a
Item-6 score 0.2 ± 0.5 1.2 ± 1.2 < 0.001a
Intracranial volume (cm3, mean ± SD) 1515.5 ± 147.7 1509.1 ± 154.1 0.805a
VPP (mm3, mean ± SD) 69.5 ± 18.5 51.7 ± 10.8 < 0.001b
Cerebral amyloid deposition (present, %) 31.9 28.2 0.643a
Abbreviations: pRBD probable REM sleep behavior disorder, SD standard deviation, AD Alzheimer’s disease, SU standard units, GDS Geriatric Depression Scale, CDR
Clinical Dementia Rating, RBDSQ REM Sleep Behavior Disorder Screening Questionnaire, VPP pineal parenchyma volume
aIndependent sample t test for continuous variables and chi-square test for categorical variables
bAnalysis of covariance adjusted for age, sex, years of education, intracranial volume, head injury, amount of smoking, amount of alcohol drinking, and use of
drugs influencing sleep or motor activity
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VPP than those without pRBD (p = 0.002). VPP was in-
versely associated with the risk of pRBD (OR = 0.901, 95%
CI = 0.840–0.966, p = 0.004), and AUC of VPP for pRBD
was 0.81 (95% CI = 0.710–0.880, p < 0.0001; Fig. 2b). The
optimal cutoff value of the VPP for classifying pRBD was
60mm3 (sensitivity = 100%; specificity = 57.32%). VPP also
showed significant inverse association with the RBDSQ-T
(standardized β = − 0.491, p < 0.001) and the RBDSQ-6
(standardized β = − 0.276, p = 0.015, Fig. 3b).
Discussion
In this cross-sectional study, we found that smaller pin-
eal parenchyma volume was associated with more RBD
symptoms in AD patients, which is in line with our pre-
vious observation that smaller pineal parenchyma vol-
ume was associated with the more RBD symptoms and
the higher risk of future pRBD in cognitively normal
older adults [16].
It is now well established that RBD is a strong pre-
dictor of neurodegeneration, in particular α-
synucleinopathies [1]. According to a previous clinico-
pathological study, 94% of the polysomnography (PSG)-
confirmed RBD patients were found to have synucleino-
pathies at autopsy [2], suggesting that the presence of
RBD in patients with dementia may favor the diagnosis
of DLB [42]. However, not all RBD patients progressed
Fig. 2 Diagnostic accuracy for the prevalent probable rapid eye movement sleep behavior disorder of the pineal parenchyma volume in a all
participants and b participants with Aβ-positive Alzheimer’s disease. Aβ, amyloid beta; VPP, pineal parenchyma volume (mm3); AUC, area under
the curve; CI, confidence interval
Fig. 3 Association between REM Sleep Behavior Disorder Screening Questionnaire total score and pineal parenchyma volume (mm3) in a all
participants and b participants with Aβ-positive Alzheimer’s disease. Multiple linear regression model adjusted for age, sex, years of education,
intracranial volume, head injury, amount of smoking, amount of alcohol drinking, and use of drugs influencing sleep or motor activity
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to neurodegenerative syndrome with synucleinopathies.
The overall conversion rate from idiopathic RBD to an
overt neurodegenerative syndrome was 6.3% per year in
the elderly adults aged 66.3 ± 8.4 years on average [43].
Furthermore¸ RBD can occur alone without any neuro-
logical conditions, and large clinical series have reported
that the idiopathic form of RBD accounts for up to 60%
of the cases [3]. Therefore, we should be more cautious
in confirming that all dementia with RBD is a synuclei-
nopathy or at least a neurodegenerative disease having
synucleinopathies as a secondary pathology. Although
synucleinopathies may be a common sufficient condition
for RBD, it is not a necessary condition for RBD.
RBD was common in clinically diagnosed AD [5, 6]
and 3–11% of polysomnography-defined RBD patients
developed AD [9–14]. In amyloid PET-confirmed AD
patients, 24.6% showed RBD in a previous study [8], and
11.8% showed pRBD in the current study. Some authors
have argued that an imbalance of acetylcholine transmis-
sion, a hallmark of AD, could explain the occurrence of
RBD in a small portion of AD patients [6]. This is based
on the findings that acetylcholine may be involved in the
induction of REM sleep atonia [15], considering that an
injection of cholinergic agonists induced muscle atonia
in dogs [44] and the administration of cholinesterase in-
hibitors augmented the amount of REM sleep [45]. The
brainstem regions also have been implicated in RBD
pathophysiology based on lesion studies in animals, es-
pecially involving pontine nuclei including the noradren-
ergic locus coeruleus (LC), cholinergic
pedunculopontine nucleus, and laterodorsal tegmental
nucleus [1]. Lesioning the LC causes REM sleep without
atonia, and size of the lesion determines whether simple
or complex behaviors are exhibited [46]. The LC is
prone to early neurodegeneration [47], and LC neurons
can be lost up to 70% in AD brains [48]. Therefore, atro-
phy of LC nuclei with impaired noradrenergic systems
may also contribute to the development of RBD in AD
patients [6].
In our previous and the current works, we demon-
strated the association of smaller pineal gland with the
risk of pRBD in both cognitively normal older adults
without any symptom or sign of neurodegenerative
disorders including synucleinopathies [16] and in AD
patients without any symptom or sign of synucleinopa-
thies. These results suggested that reduced endogenous
melatonin production may be another cause of RBD in
AD patients as well as in normal older adults because
the secretion of melatonin was strongly associated with
pineal gland volume. Compared to healthy controls, AD
patients showed disrupted circadian melatonin rhythm,
lower melatonin levels in the cerebrospinal fluid, serum
and postmortem pineal gland [17], and smaller pineal
parenchyma [18]. Since the pineal gland is a
circumventricular organ surrounded by the cerebro-
spinal fluid [19], it can be easily influenced by soluble
Aβ peptides [49]. A previous in vitro study of isolated
rat pineal glands confirmed that Aβ directly inhibited
pineal melatonin synthesis and impaired melatonergic
systems, leading to a neuroinflammatory response within
the gland [49]. Therefore, enduring insults of Aβ may re-
duce pineal gland volume and melatonin production,
which may increase the risk of RBD in AD patients. In
addition, under physiological conditions, melatonin
in vivo protects central cholinergic neurons against Aβ-
mediated toxicity via its antioxidant and anti-
amyloidogenic properties [50]. Melatonin not only in-
hibits Aβ generation but also arrests the formation of
amyloid fibrils by a structure-dependent interaction with
Aβ [50]. Therefore, reduced melatonin production due
to pineal atrophy may also increase the risk of RBD or
worsen RBD symptoms in AD patients indirectly via re-
duced protection of the cholinergic system from amyloid
toxicity.
Limitations
Our study has several methodological limitations. First,
we used a questionnaire to determine if a participant
was at a high risk of RBD, whereas video PSG is required
to establish the definitive diagnosis of RBD [1]. This
could be a substantial problem when the participants
have significant cognitive impairments such as AD, lead-
ing to a recall bias. However, considering that the previ-
ous reports have suggested that the prevalence of PSG-
confirmed RBD in AD subjects ranges from 5% (mean
age [SD], 70.5 [9.4]; mean disease duration of AD, 16.1
[7.1] months) [6] to 27% (mean age, 70.2 [5.6] with glo-
bal deterioration scale score of 3 or 4 [5], our results,
with the prevalence of pRBD of 13% (mean age, 77.3
[7.4]; mean disease duration of AD, 37.8 [27.6] months),
seem to be in a reasonable extent. Additionally, we ob-
tained the RBDSQ data with the corroboration from the
participant’s partners, which could increase their validity.
Second, although we strictly excluded AD patients who
simultaneously met the diagnostic criteria for possible or
probable DLB, it is still possible that our study samples
could have included the patients with synucleinopathies
because clinical features between AD and DLB are over-
lapping [51] and 40–50% of AD patients had α-
synuclein-positive Lewy bodies [52–54]. In addition, we
did not conduct brain dopamine transporter scan or
metaiodobenzylguanidine myocardial scan which would
have helped to rule out DLB more definitively. However,
even in synucleinopathies, the pineal gland may be asso-
ciated with the risk of RBD because melatonin also
played a protective role against synucleinopathies [55].
Third, causal relationship between pineal gland volume
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and pRBD cannot be inferred because the current study
employed a cross-sectional design.
Conclusion
In conclusion, the current study suggests that smaller
pineal gland may be associated with the risk and/or se-
verity of RBD in AD patients.
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